Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
IROpus Genetics, Inc. logo

Opus Genetics, Inc. (IRD)

NASDAQ Global Market · Currency in USD
$3.47 ▼ -0.35 (-9.16%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.52 ▲ +0.05 (+1.44%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.82
Open
$3.79
Day's Range
$3.44 – $3.80
52 Week Range
$1.70 – $7.07
Volume
1,116,709
Avg. Volume
2,106,448
Market Cap
$288.69M
Beta (5Y Monthly)
0.62
PE Ratio (TTM)
--
EPS (TTM)
-$1.13
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.60

Profile: Opus Genetics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
28
CEO
George Magrath

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.14 · Revenue est. $1.55M
DateEst.Actual
Aug 6, 2026-$0.16-$0.14Beat
May 12, 2026-$0.16-$0.75Miss
Mar 10, 2026-$0.11-$0.14Miss
Nov 12, 2025-$0.14-$0.25Miss
Aug 13, 2025-$0.25-$0.12Beat
May 15, 2025-$0.34-$0.24Beat

Analyst view

Consensus price target
$12.60 ▲ +263.1%
Range $8.00 – $20.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on IRD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.